United Kingdom: Life Sciences, Biotechnology & Nanotechnology

Building on my previous article relating neurotech to European patentability exclusions, I will discuss how the novelty of medical devices is assessed differently from pharmaceuticals.

Globally, market volatility has eroded confidence and subdued M&A activity. A "wait and see" approach is the prevailing sentiment for many market participants...

In the latest of our articles about the UK government's industrial strategy and sector plans, we're now taking a look at its tech and digital sector plan.

Globally, patent protection for polymorphs continues to evolve, with different jurisdictions applying nuanced (and often inconsistent) tests for patentability.

On 11 April 2025, the MHRA announced that the much anticipated changes to the clinical trial rules in the UK, the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2024 (the new Regulations)...

We, as Socius, want to move away from the traditional out of town science park – we don't believe that is the right approach to attract talent and create a vibrant, living community.

This update focuses on: the new clinical trials legal framework designed to heighten interest for planning and conducting clinical trials in the EU; the UK government's new migration regime to make it easier for businesses to hire highly skilled workers in sectors such as life sciences; digital transformation in the life sciences sector; the outlook for M&A activity in pharmaceuticals and life sciences; and the latest on longevity in life sciences.

Donald Trump's return to the White House has brought with it some fast-paced changes to global politics and markets, and the biotech industry has not been left out from the speculation about the future.

PAGB published its updated Professional Code for Medicines (the Code) on 12 February 2025.